Dapagliflozin-Sitagliptin in T2D: Moving Beyond HbA1c Towards a Broader Orbit of Care

Type 2 diabetes (T2D) is increasingly recognised as a complex gluco-cardio-metabolic disease requiring more than glycaemic control alone. India has nearly 89.8 million adults living with diabetes, with an age-adjusted prevalence of 10.5%; approximately 43% remain undiagnosed, while over 107 million adults have impaired fasting glucose. Importantly, cardiovascular risk is already substantial at diagnosis; In a study including 5,080 newly diagnosed Indian patients with T2D, 39.5% were classified as high and 60.5% as very high ASCVD risk, with a mean QRISK3-estimated 10-year cardiovascular risk of 15.3%. This reinforces the need for early treatment strategies addressing glycaemic, metabolic, and cardiorenal risk together in T2D care. Consequently, treatment goals have evolved towards durable glycaemic control, weight and metabolic benefits, cardiorenal protection, while ensuring low hypoglycaemia risk, treatment simplicity, and sustained adherence. ^1-3

Beyond HbA1c: Defining the Modern Treatment Goals in T2D

Contemporary T2D management is no longer defined by achieving HbA1c targets alone. The ADA Standards of Care 2026 advocate a person centred approach, recommending that therapeutic decisions be guided by individualized glycaemic and weight goals, the presence of cardiovascular, kidney, and other metabolic comorbidities, hypoglycaemia risk, treatment burden, and medication complexity.

These attributes now represent the modern treatment checklist for optimizing outcomes in people with T2D. ^{4, 5}

Dapagliflozin & Sitagliptin - Complementary Potential of Two Widely Experienced Agents

The complementary pharmacological profiles of dapagliflozin and sitagliptin enable a multidimensional approach to diabetes management by targeting distinct yet synergistic pathophysiological pathways. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, lowers plasma glucose through insulin-independent urinary glucose excretion, while sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin activity to stimulate glucose-dependent insulin secretion and suppress glucagon release. Both these agents have wide clinical experience globally and in India.

Together, these complementary mechanisms provide effective and durable glycaemic control with a low intrinsic risk of hypoglycaemia. Beyond glycaemic efficacy, dapagliflozin offers additional benefits on body weight reduction, blood pressure lowering, and cardiorenal health, whereas sitagliptin provides sustained glucose lowering with established cardiovascular safety and weight neutrality.

Furthermore, the availability of the combination as a fixed-dose formulation reduces pill burden, simplifies treatment, and may improve long-term adherence. By addressing multiple contemporary treatment priorities within a single regimen, the dapagliflozin–sitagliptin combination represents a rational and patient centred therapeutic strategy for the comprehensive management of T2D. ^{4, 6}

Figure 1: Dapagliflozin and Sitagliptin: Individual & Complementary Strengths in the T2D Orbit of Care ^{4, 6-9}

Dapagliflozin & Sitagliptin: Promising Recent Indian Clinical Evidence

The growing role of the dapagliflozin–sitagliptin fixed-dose combination (FDC) in Indian T2D management is supported by recent expert consensus and real-world evidence.

Dapagliflozin Sitagliptin FDC – AACE 2026 Update: At the AACE 2026 Annual Meeting, the DIMETRIC Consensus Mapping, representing over 2,000 cumulative clinician-years of experience was presented, showed strong agreement on the FDC’s complementary glycaemic effects across diverse T2D phenotypes (weighted score [WS] 121.3), early use in patients at high cardiovascular risk (WS 125.9), effectiveness and tolerability in Indian practice (WS 124.7), and potential to reduce therapeutic inertia (WS 117.2). Together, these findings support the dapagliflozin–sitagliptin FDC as a practical option for holistic metabolic management with benefits extending across glycemic, renal, weight and blood pressure parameters in routine Indian T2D care.⁷

These recommendations are reinforced by the BRIDGE-DS studies published over the last year.

BRIDGE-DS Indian Study 1 – T2D with High CV Risk: In a multi-centre retrospective study of 1,093 Indian patients with T2D and established ASCVD or high cardiovascular risk, 3 months of therapy reduced HbA1c from 8.9% to 7.4% (-1.5%), fasting glucose from 173.0 to 129.3 mg/dL (43.7 mg/dL reduction), postprandial glucose from 257.2 to 185.2 mg/dL (72.0 mg/dL reduction), systolic blood pressure from 150.5 to 131.5 mmHg (19.0 mmHg reduction), and Framingham Risk Score from 15.9% to 9.4% (6.5% reduction) (all P<0.001). ⁸

BRIDGE-DS Indian Study 2 – T2D with HF: In a higher CV risk cohort including 168 patients with T2D and heart failure, HbA1c declined from 8.9% to 7.4% (1.5% reduction), NT-proBNP from 306.7 to 184.0 pg/mL (122.7 pg/mL reduction), and blood pressure SBP/DBP from 151/98 to 133/87 mmHg (18/11 mmHg reduction) over 3 months. LVEF increased from 43.1% to 46.0% (2.9% increase) and eGFR from 63.1 to 74.0 mL/min/1.73 m² (10.9 mL/min/1.73 m² increase) (all P<0.0001), with acceptable tolerability. ⁹

Altogether, these findings connect expert consensus with measurable real-world outcomes, supporting the dapagliflozin-sitagliptin FDC as a practical consideration for integrated glycaemic and cardiorenal management in Indian patients with T2D.

Key Takeaway Message

• Contemporary T2D care must move beyond HbA1c reduction to simultaneously address weight, hypoglycaemia risk, cardiorenal vulnerability, treatment burden, and long-term adherence. ^{1, 2}
• Through complementary insulin-independent and incretin-based mechanisms, dapagliflozin–sitagliptin provides a rational fixed-dose strategy approach for integrated glycaemic, metabolic, and cardiorenal management. ^{4, 6}
• Recent Indian evidence published over last two years further reinforces its effectiveness, tolerability, and practical relevance across high-risk T2D phenotypes, provided treatment is individualized to renal function, comorbidities, safety, and patient preference. ^7-9

**Abbreviations: T2D: Type 2 Diabetes; HbA1c: Glycated Haemoglobin; CV: Cardiovascular; ASCVD: Atherosclerotic Cardiovascular Disease; SGLT2: Sodium-Glucose Cotransporter-2; DPP-4: Dipeptidyl Peptidase-4; FDC: Fixed-Dose Combination; ADA: American Diabetes Association; AACE: American Association of Clinical Endocrinology; DIMETRIC: Dapagliflozin–Sitagliptin Consensus Mapping; WS: Weighted Score; HF: Heart Failure; CKD: Chronic Kidney Disease; eGFR: Estimated Glomerular Filtration Rate; NT-proBNP: N-terminal pro-B-type Natriuretic Peptide; LVEF: Left Ventricular Ejection Fraction; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; IR: Insulin Resistance; QRISK3: Third version of the QRISK cardiovascular risk prediction algorithm; FPG: Fasting Plasma Glucose; PPG: Postprandial Glucose.